-+ 0.00%
-+ 0.00%
-+ 0.00%

Maiwei Biotech announced that the company plans to increase capital and transfer TCE project assets to its wholly-owned subsidiary Lianwei Chuangyuan. Lianwei Chuangyuan plans to sign a pre-A round capital increase agreement with 5 investors, with a total investment of 160 million yuan. After the capital increase is completed, Lianwei Chuangyuan's registered capital will increase to 116 million yuan, and the company expects to hold 71.21% of its shares.

Zhitongcaijing·09/28/2026 11:01:02
Listen to the news
Maiwei Biotech announced that the company plans to increase capital and transfer TCE project assets to its wholly-owned subsidiary Lianwei Chuangyuan. Lianwei Chuangyuan plans to sign a pre-A round capital increase agreement with 5 investors, with a total investment of 160 million yuan. After the capital increase is completed, Lianwei Chuangyuan's registered capital will increase to 116 million yuan, and the company expects to hold 71.21% of its shares.